A biosimilar is a biological medicinal product that is highly similar to an already approved reference biological (originator) and shows no clinically meaningful differences in terms of safety, purity, and efficacy. Due to the inherent variability of biological production systems, biosimilars are not identical to the reference product; however, they must undergo extensive comparability studies to demonstrate similarity. The development of biosimilars follows abbreviated pathways, enabling significant cost and time savings.
The development of biosimilars requires sophisticated analytical characterization to perform a comprehensive similarity assessment between the biosimilar and the reference product. CROs must develop specialized analytical capabilities for physicochemical characterization, biological activity assessment, and immunogenicity testing. Clinical biosimilar studies focus on pharmacokinetic/pharmacodynamic similarity and clinical efficacy comparability.
Regulatory pathways for biosimilars vary between authorities such as the FDA and EMA. CROs must understand region-specific requirements and implement appropriate development strategies. Market access for biosimilars involves complex considerations, including interchangeability designations and acceptance among physicians and patients.